Norja -
norja -
Statens legemiddelverk
norspan 10 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 10 mikrog/ time
Norja -
norja -
Statens legemiddelverk
norspan 15 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 15 mikrog/ time
Norja -
norja -
Statens legemiddelverk
norspan 30 mikrog/ time
mundipharma as - buprenorfin - depotplaster - 30 mikrog/ time
Norja -
norja -
Statens legemiddelverk
bugnanto 15 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 15 mikrog/ time
Euroopan unioni -
norja -
EMA (European Medicines Agency)
gencebok
gennisium pharma - koffein citrate - apnea - psychoanaleptics, - behandling av primær apnoea av premature nyfødte.
Norja -
norja -
Statens legemiddelverk
bugnanto 5 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 5 mikrog/ time
Norja -
norja -
Statens legemiddelverk
bugnanto 10 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 10 mikrog/ time
Norja -
norja -
Statens legemiddelverk
bugnanto 20 mikrog/ time
sandoz - københavn - buprenorfin - depotplaster - 20 mikrog/ time
Norja -
norja -
Statens legemiddelverk
pentoxin 500 mg/ ml
chanelle pharmaceuticals manufacturing ltd - pentobarbitalnatrium - injeksjonsvæske, oppløsning - 500 mg/ ml
Euroopan unioni -
norja -
EMA (European Medicines Agency)
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - Øyemidler - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.